Cody Moore
Director - Platform Development iBio
Seminars
Wednesday 2nd December 2026
Decoding Amylin Receptor Specificity to Engineer a More Precise, Long Acting Therapeutic
1:30 pm
- Explore how fully selective antibodies can distinguish between AMY1, AMY3 and calcitonin receptor activity, moving beyond broadly biased peptide agonists to identify which receptor profiles drive weight loss, tolerability and body-composition outcomes
- Examine how parallel interrogation of G-protein and β-arrestin signaling can connect cellular mechanism with in vivo performance, enabling more rational optimization of potency, signaling bias and receptor engagement rather than relying on clinical trialand-error
- Assess the potential of ultra-long-acting amylin antibodies to deliver infrequent dosing, sustained receptor coverage and improved treatment adherence, helping developers pursue durable efficacy while reducing adverse effects, treatment burden and weight cycling
